|
|||||
|
|
A phase 1 study of the c‐Met inhibitor,tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111) |
|
| Authors: | James I. Geller John P. Perentesis Xiaowei Liu Charles G. Minard Rachel A. Kudgus Joel M. Reid Elizabeth Fox Susan M. Blaney Brenda J. Weigel |
| Affiliation: | 1. Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH;2. Children's Oncology Group, Monrovia, CA;3. Dan L. Duncan Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX;4. Mayo Clinic, Rochester, MN;5. Children's Hospital of Philadelphia, Philadelphia, PA;6. Masonic Children's Hospital, University of Minnesota Medical Center, Minneapolis, MN |
| Abstract: | |
| Keywords: | |